GlobeNewswire

Jumio Records Best Sales Quarter in Company History, Fueled by Q2 Growth in Asia Pacific

Dela

Jumio Records Best Sales Quarter in Company History, Fueled by Q2 Growth in Asia Pacific

Jumio's sales grew by more than 200 percent year over year for three of our last four quarters; the company has recorded quarter over quarter sales growth nine of the last ten quarters

PALO ALTO, Calif., July 10, 2018 (GLOBE NEWSWIRE) -- Jumio, the leading AI-powered trusted identity as a service provider, today announced its best sales quarter in company history, ending June 30, 2018, representing a 269 percent increase in sales over the same quarter last year. The results were fueled by record sales growth in the Asia Pacific region, which grew 531 percent over the previous quarter.

"We're thrilled that within three months of opening our Singapore office, Asia Pacific has already generated so much in sales and has seen such wide adoption," said Steve Stuut, CEO of Jumio. "This type of immediate market traction speaks to the opportunity this region represents and the untapped potential, especially within financial services, enterprise and e-commerce markets."

The emerging need for reliable digital identity verification, coupled with increasingly stringent data protection and privacy regulations (e.g., GDPR and California Consumer Privacy Act) and the growing realization that traditional authentication methodologies are no longer effective or secure, has caused companies to explore the identity-verification-as-a-service market.

According to a market study by McKinsey, the emerging identity-verification-as-a-service market is close to $10 billion and predicts it will grow to a $16-20 billion market by 2022. McKinsey reports, "Identity verification-as-a-service offers a way for e-commerce providers to outsource the verification function to providers with the necessary scale and security to accomplish sensitive transactions quickly, safely, and efficiently." In fact, the Asia Pacific market is growing almost 50 percent faster than the North America and Western European markets because of the higher volume of digital transactions that require online identity verification.

Increased awareness and familiarity with identity verification has helped fuel Jumio's continued momentum as the company reports its strongest quarter in company history, including these notable milestones:

  • Six Straight Quarters of Sales Growth: Jumio grew sales nine of the past ten quarters, demonstrating growing traction for its online ID and identity verification solutions. Its focus on compliant machine learning, leading-edge identity proofing technologies, and a customer-centric mentality have helped Jumio set the bar for online identity verification accuracy and gain significant market share.
  • AsiaPac Expansion: In Q2, Jumio saw its Asia Pacific sales grow significantly and signed two of the largest deals in the company's history as a result of having a dedicated regional focus, which includes a new Singapore office and expanded sales presence to support the region's growing demand for online digital identity verification and Know Your Customer (KYC) services. 
  • Liveness Detection for Web: Jumio launched Liveness Detection for Web to ensure that the online user is physically present during the identity verification process when using their computer's webcam. This new functionality requires the user to take a picture of themself holding a handwritten note with a custom phrase (e.g. company name) and the current date, to ensure a real person is performing the transaction. 
  • Executive Hires: In Q2, Jumio hired several new executives to further strengthen its leadership team and support its aggressive growth objectives, including: Miles Hutchinson, Chief Information Security Officer; Mike O'Callaghan,Vice President Global Operations; and Amy Treadwell, Global Vice President of People and Culture. Together, the three new hires bring decades of leadership experience in high-growth SaaS and technology organizations.
  • Industry Recognition: Jumio continues to be recognized for its product innovation, including being awarded the Gold winner in Information Security and Risk Management (and Bronze winner for Security Software) in the 13th Annual 2018 IT World Awards®, named Best Product in Biometrics and Hot Company in Fraud Prevention by the 2018 InfoSec Awards, and named the winner in the Best Authentication Technology category by the 2018 SC Awards. Jumio was also included as a Representative Vendor in the "Market Guide for Identity Proofing and Corroboration," published by Gartner, a leading information technology research and advisory company.

For live demonstrations of the Netverify ID, Identity and Document Verification solutions, visit Jumio at the iGB Live show (Stand T7) this month in Amsterdam.

About Jumio
When identity matters, trust Jumio. Jumio is the creator of Netverify® which enables businesses to increase customer conversions while providing a seamless customer experience and reducing fraud. By combining the three core pillars of ID Verification, Identity Verification and Document Verification, businesses now have a complete solution that allows them to establish the real-world identity of the consumer.

Leveraging advanced technology including augmented AI, biometric facial recognition, machine learning, and human review, Jumio helps organizations to meet regulatory compliance including KYC, AML and GDPR and definitively establish the digital identity of their customers. Jumio has verified more than 120 million identities issued by over 200 countries from real time web and mobile transactions. Jumio's solutions are used by leading companies in the financial services, sharing economy, cryptocurrency, retail, travel and online gaming sectors. Based in Palo Alto, Jumio operates globally with offices in the US, Europe, and Asia Pacific and has been the recipient of numerous awards for innovation. For more information, please visit www.jumio.com.

Media Contacts
U.S. Media Contact
Jackie Daane
10Fold Communications
Jumio@10fold.com
415-800-5369

Europe Media Contact
Zarina Banu
FleishmanHillard Fishburn
zarina.banu@fhflondon.co.uk
+44 (0) 7775 557578

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/d1c780f4-0c16-40b0-acea-f900be5545a4




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Jumio Corp. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum